Blog
RSS FeedPosted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 30 Aug 2023
Mitsubishi Tanabe Pharma Canada announces that company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in New Brunswick and Nova Scotia
29 August 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the New ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 18 Jul 2022
More children now eligible for cystic fibrosis drug
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
Posted by Michael Wonder on 09 Feb 2022
Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program
5 February 2022 - The province is the latest jurisdiction to adopt a program that will require patients to switch ...
Posted by Michael Wonder on 15 Dec 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...
Posted by Michael Wonder on 14 Aug 2021
Halifax man devastated after insurer reverses decision to cover $25,000 cystic fibrosis drug
13 August 2021 - Stefan Strecko says he's pleaded with Canada Life to cover cost of 'miracle' drug. ...
Posted by Michael Wonder on 23 May 2021
'I would be able to live into my thirties:' Nova Scotia woman has high hopes for new cancer treatment
21 May 2021 - Maria Stevens was diagnosed with cervical cancer two years ago. Now, with a new treatment on ...
Posted by Michael Wonder on 26 Feb 2020
N.S. father says drug-pricing 'chess game' cost his daughter her life
25 February 2020 - A father's fight to bring 'life-saving' drugs to Canada. ...
Posted by Michael Wonder on 14 Feb 2020
AbbVie's Skyrizi now listed on the Nova Scotia formulary for the treatment of moderate to severe plaque psoriasis
13 February 2020 - Nova Scotia lists Skyrizi on its provincial formulary effective February 06, 2020. ...
Posted by Michael Wonder on 09 Feb 2020
N.S. senior blasts province over blood thinner coverage under pharmacare
6 February 2020 - Province covers warfarin, but it requires closer monitoring than newer, more expensive alternative, apixaban. ...
Posted by Michael Wonder on 06 May 2019
Why one Nova Scotia boy is being treated with drugs that cost $6 million a year despite a better, cheaper alternative
5 May 2019 - Last summer, Health Canada approved a haemophilia drug called Hemlibra that has the potential to change Callum ...